

**Table S1: Description of initial regimens prescribed between January 1, 2019 and November 30, 2020**

<b>Initial regimen</b>	<b>N (%)</b>
BIC/FTC/TAF	158 (50.3)
DTG+FTC/TDF	50 (15.9)
DTG/ABC/3TC	24 (7.6)
DRV/COBI/FTC/TAF	24 (7.6)
EVG/COBI/FTC/TAF	11 (3.5)
RAL+FTC/TDF	11 (3.5)
DTG/3TC	10 (3.2)
DTG+FTC/TAF	9 (2.9)
EFV/FTC/TDF	7 (2.2)
RAL+FTC/TAF	4 (1.3)
RAL+3TC/ABC	2 (0.6)
DRV+RTV+FTC/TDF	1 (0.3)
EFV+FTC/TAF	1 (0.3)
RAL+ETR/FTC	1 (0.3)
RPV+FTC/TAF	1 (0.3)

**Table S2: Selection of the study population for the ITT and OT analyses of VS and IR at 24 and 48 weeks after ART initiation**

	At 24 ( $\pm$ 12) weeks			At 48 ( $\pm$ 12) weeks		
	Total N = 314	BIC/FTC/TAF N = 158	Other regimens N = 156	Total N = 314	BIC/FTC/TAF N = 158	Other regimens N = 156
<b>Overall exclusions</b>						
Death before the assessment window	5 (1.6)	1 (0.6)	4 (2.6)	11 (3.5)	3 (1.9)	8 (5.1)
AIDS-related death	3 (1.0)	1 (0.6)	2 (1.3)	8 (2.5)	2 (1.3)	6 (3.8)
Death to non-AIDS infection	0	0	0	1 (0.3)	1 (0.6)	0
Death due to MI or other ischemic heart disease	1 (0.3)	0	1 (0.6)	1 (0.3)	0	1 (0.6)
Death due to other causes	1 (0.3)	0	1 (0.6)	1 (0.3)	0	1 (0.6)
Last visit to the centre before the assessment window	6 (1.9)	2 (1.3)	4 (2.6)	16 (5.1)	9 (5.7)	7 (4.5)
No visit in the assessment window	10 (3.2)	3 (1.9)	7 (4.5)	14 (4.5)	5 (3.2)	9 (5.8)
<b>Exclusions for VS analyses</b>						
	6 (1.9)	5 (3.2)	1 (0.6)	9 (2.9)	4 (2.5)	5 (3.2)

Available visit in the assessment window but missing viral load	<b>287 (91.4)</b>	<b>147 (93.0)</b>	<b>140 (89.7)</b>	<b>264 (84.1)</b>	<b>137 (86.7)</b>	<b>127 (81.4)</b>
	39 (13.6)	4 (2.7)	35 (25.0)	59 (22.3)	10 (7.3)	49 (38.6)
<b>ITT analyses</b>	<b>248 (79.0)</b>	<b>143 (90.5)</b>	<b>105 (67.3)</b>	<b>205 (65.3)</b>	<b>127 (80.4)</b>	<b>78 (50.0)</b>
Treatment discontinuation before 24 or 48 weeks, as appropriate <sup>1</sup>						
<b>OT analyses</b>	11 (3.5)	5 (3.2)	6 (3.8)	17 (5.4)	8 (5.1)	9 (5.8)
	<b>282 (89.8)</b>	<b>147 (93.0)</b>	<b>135 (86.5)</b>	<b>256 (81.5)</b>	<b>133 (84.2)</b>	<b>123 (78.8)</b>
<b>Exclusions for IR analyses</b>	38 (13.5)	4 (2.7)	34 (25.2)	59 (23.0)	10 (7.5)	49 (39.8)
Available visit in the assessment window but missing CD4	<b>244 (77.7)</b>	<b>143 (90.5)</b>	<b>101 (64.7)</b>	<b>197 (62.7)</b>	<b>123 (77.8)</b>	<b>74 (47.4)</b>
<b>ITT analyses</b>						
Treatment discontinuation before 24 or 48 weeks, as appropriate <sup>1</sup>						
<b>OT analyses</b>						

ITT: Intention to treat. OT: On treatment. VS: virological suppression. IR: immunological recovery. MI: myocardial infarction.

All percentages are calculated over the total number of individuals in each group, except those for <sup>1</sup>Treatment discontinuation before 24 or 48 weeks, as appropriate, that are calculated over the total number of individuals included in the ITT analyses.